Your Questions, Answered
We’ve assembled the most frequently asked questions about Eversense into one place. Got a question that you can’t find the answer to? Contact us.
The glucose data is stored in the cloud, not on your mobile device. If you are downloading the App onto a new device, the following data will automatically become available:
- Last 3 hours of glucose data
- Last 20 events
- Last 20 glucose alerts
For security purposes if you enter an incorrect password three consecutive times in the mobile app, your account will be locked for 30 minutes. During this time, you will not have access to your Eversense NOW account.
If you enter an incorrect password three times on your DMS log in page, functionality in the Eversense NOW app will be unavailable for 30 minutes.
DO NOT insert your infusion set within 4 inches (10.16 cm) of the sensor site. If the insulin delivery site is within 4 inches (10.16 cm) of the sensor site, it may interfere with sensor glucose readings and can cause inaccurate glucose readings.
It is safe for you to wear your sensor and smart transmitter when you go through metal detectors at airports. While flying, the smart transmitter performs similar to any other Bluetooth® device. Be sure to follow the specific safety guidelines mandated by the airline.
If you have insurance, your out of pocket cost will vary depending on your coverage and plan. If interested & qualified, we'd run a benefit investigation with your insurance company to confirm the cost.
If you're on commercial insurance, we have the PASS program that means you could pay as low as $199 for a full year. This includes the cost of both CGM sensor and transmitter.*
If you don't have insurance, call us at (945) 221-9068 to discuss cash-pay options.
Still have questions?
The Eversense team is dedicated and ready to provide the answers and support you need. Simply click the link below.
The Eversense® E3 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to 180 days in persons with diabetes age 18 and older. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are still required for calibration primarily one time a day after day 21, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense E3 CGM System is a prescription device; patients should talk to their health care provider to learn more.
The Eversense® 365 Continuous Glucose Monitoring (CGM) System is indicated for continually measuring glucose levels for up to one year in people (18 years and older) with diabetes. The system is indicated for use to replace fingerstick blood glucose (BG) measurements for diabetes treatment decisions. Fingerstick BG measurements are required for calibration one time a week after day 13, and when symptoms do not match CGM information or when taking medications of the tetracycline class. The sensor insertion and removal procedures are performed by a health care provider. The Eversense 365 CGM System is a prescription device; patients should talk to their health care provider to learn more.
For important safety information, see bit.ly/eversensesafety
Eversense, Eversense E3 Continuous Glucose Monitoring, Eversense 365 Continuous Glucose Monitoring, and the Eversense logo are trademarks of Senseonics, Incorporated. Ascensia, the Ascensia Diabetes Care logo are trademarks and/or registered trademarks of Ascensia Diabetes Care Holdings AG. All other trademarks are properties of their respective owners and are used solely for informative purposes. No relationship or endorsement should be inferred or implied.
Apple Watch® is a product of Apple, Inc., and may be separately purchased from an authorized Apple retailer. Apple Watch is not included with the Eversense CGM System. Android is a trademark of Google LLC.
PP-SENS-E3-GBL-0060